🏷️ LIMITED TIME OFFER: GET 20% OFF GRADE+ YEARLY SUBSCRIPTION →
Log in
HomeClass Notes1,200,000CA670,000

MIMM 387 Lecture : april 2 2012.docx

39 views6 pages
School
McGill University
Department
Microbiology and Immun (Sci)
Course
MIMM 387
Professor
Robert Murgita

For unlimited access to Class Notes, a Class+ subscription is required.

Document Summary

It is the same group reviewing (federal government). Health care in terms of delivery is under provincial jurisdiction. So the right to health care is a national one, and the delivery is provincial. If you look at units (on the left), in terms of units the amount of generic usage and brands is. Products that are still under patent protection have little or no cost control, and a lot of these are biologics. So we are no longer talking about the traditional molecules. Due to the erosion of prices that has happened, generics price has dropped. Since 2010, prices has dropped by another 25%. In the 2010-2011 budget for ontario, 45% was health care. Remember, they need to buy a lot of other things as well. It is estimated that at the rate it is going, at 12 years it is 70% of the provincial budget.

Get access

Grade+20% off
$8 USD/m$10 USD/m
Billed $96 USD annually
Grade+
Homework Help
Study Guides
Textbook Solutions
Class Notes
Textbook Notes
Booster Class
40 Verified Answers
Class+
$8 USD/m
Billed $96 USD annually
Class+
Homework Help
Study Guides
Textbook Solutions
Class Notes
Textbook Notes
Booster Class
30 Verified Answers

Related Documents

Health Sciences 3400A/B Lecture Notes - Lecture 3: Canada Health Act, Canada Health Transfer, Territorial Formula Financing
raspberrypig639
SOSC 2330 Lecture Notes - Lecture 6: Consumer Protection, Generic Drug, Imperfect Competition
bluecockroach306
HSCI 305 Lecture Notes - Lecture 5: Canada Health Infoway, Canada Health Transfer, Provincial Health Services Authority
cynnk

Related Questions

Your company, DrugsRUs, has developed a generic angiotensin-converting-enzyme inhibitor, Vasotec, as a pharmaceutical drug used primarily for the treatment of hypertension and congestive heart failure. You are leading the regulatory strategy team and have been asked to describe the path to approval comparing introduction in the US versus Brasil.

Please discuss the following:

(1) Which agency or agencies will be responsible for approving/reviewing your Vastec drug: (a) before commercial introduction, and (b) after approval for commercialization/sale within the US., and

(2) Compare known issues your company will need to consider to market your generic drug is Brasil.

According to the Sullivan Commission report of 2004 what is a major contributor to the health care delivery disparity problem? a.The disparity in the health care workforce. b. Miinority underrepresentation on governmental task forces to improve services. c. Unwillingness of minority populations to take responsibility for their own health needs. d. The increasing minority population will soon outnumber the traditional majority population numbers.

Dewey Cheatham is the new Vice President of Marketing for a large online search engine company, Pottstown Innovative Enterprises (AKA, PIE). Dewey has been doing some research into how he can increase the Company’s revenues and thereby really impress the Company brass. During his research he came across an article about Brazilian pharmacies looking for an advertising vehicle to tap into the U.S. consumer market. Further research reveals that this could be a billion dollar venture and if PIE plays its cards right, it could make a substantial amount of money given its extensive advertising network. Dewey is super ecstatic about the possibilities and is salivating over what this could mean for his career with PIE.

Before Dewey pulls the trigger on this, he decides to consult with his legal department. The legal department tells Dewey the following:

1. The shipment of prescription drugs from pharmacies outside the United States to customers in the United States may violate the Federal Food, Drug and Cosmetic Act and in the case of controlled prescription drugs, the Controlled Substances Act.

2. The FDA cannot ensure the safety and effectiveness of foreign prescription drugs that are not FDA-approved.

3. Imported drugs typically do not meet FDA’s labeling requirements and may not have been manufactured, stored and distributed under proper conditions; and may not have been dispensed in accordance with a valid prescription.

4. The government has historically been very lax in enforcing the laws in this area and legally there are a few gray areas; therefore the risk of any prosecution may not be significant.

After the consultation with Legal, Dewey is confused as to what his decision should be. If you were advising Dewey on the ethical implications presented by this case, what would you say to him? Specifically, what ethical problems and issues do you see?